Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Orchestra BioMed Holdings (OBIO) Research & Development (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Research & Development for 4 consecutive years, with $16.8 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 53.34% to $16.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $58.2 million through Dec 2025, up 35.93% year-over-year, with the annual reading at $58.2 million for FY2025, 35.93% up from the prior year.
  • Research & Development for Q4 2025 was $16.8 million at Orchestra BioMed Holdings, up from $14.0 million in the prior quarter.
  • The five-year high for Research & Development was $16.8 million in Q4 2025, with the low at $3.5 million in Q1 2022.
  • Average Research & Development over 4 years is $9.8 million, with a median of $8.8 million recorded in 2023.
  • The sharpest move saw Research & Development soared 137.59% in 2023, then increased 10.39% in 2024.
  • Over 4 years, Research & Development stood at $7.5 million in 2022, then rose by 12.83% to $8.5 million in 2023, then rose by 28.9% to $11.0 million in 2024, then surged by 53.34% to $16.8 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $16.8 million, $14.0 million, and $13.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.